BACKGROUND: Although cancer cachexia is widely diffuse in the cancer patient population, there is no objective definition and classification of this syndrome. The purpose of this study is to propose a simple and quick classification that relies on the severity of the body weight loss and presence/absence of symptoms that are associated with cancer cachexia. METHODS: The authors used a database of an ongoing multicenter prospective investigation on the screening of the nutrition risk of 1307 cancer outpatients from different (mainly Italian) university or scientific institutes or hospitals. The database included demographic, oncologic, clinical, and nutrition data. The patients were divided into 4 classes based on combinations of body weight loss (< 10%, precachexia; > or = 10%, cachexia) and the presence/absence of at least 1 symptom of anorexia, fatigue, or early satiation. The authors verified statistically whether these 4 classes were associated with the distribution of main clinical, nutrition, and oncologic variables, after adjustment for treatment status, by using the Cochrane-Mantel-Hanszel test for count data and ANOVA for continuous data. RESULTS: Moving from "asymptomatic precachexia" (class 1) to "symptomatic cachexia" (class 4), there were statistically significant trends (P < .0001) in the percentage of gastrointestinal vs nongastrointestinal tumors, severity of cancer stage, percentage of weight loss, number of symptoms per patient, Eastern Cooperative Oncology Group (ECOG) performance status, and nutritional risk score. CONCLUSIONS: The statistical analysis has validated the classification by identifying stages with different severity of cachexia. This classification could be adopted within a comprehensive oncologic approach to the weight-losing patients, until more specific diagnostic techniques are available in clinical practice.
BACKGROUND: Although cancer cachexia is widely diffuse in the cancerpatient population, there is no objective definition and classification of this syndrome. The purpose of this study is to propose a simple and quick classification that relies on the severity of the body weight loss and presence/absence of symptoms that are associated with cancer cachexia. METHODS: The authors used a database of an ongoing multicenter prospective investigation on the screening of the nutrition risk of 1307 cancer outpatients from different (mainly Italian) university or scientific institutes or hospitals. The database included demographic, oncologic, clinical, and nutrition data. The patients were divided into 4 classes based on combinations of body weight loss (< 10%, precachexia; > or = 10%, cachexia) and the presence/absence of at least 1 symptom of anorexia, fatigue, or early satiation. The authors verified statistically whether these 4 classes were associated with the distribution of main clinical, nutrition, and oncologic variables, after adjustment for treatment status, by using the Cochrane-Mantel-Hanszel test for count data and ANOVA for continuous data. RESULTS: Moving from "asymptomatic precachexia" (class 1) to "symptomatic cachexia" (class 4), there were statistically significant trends (P < .0001) in the percentage of gastrointestinal vs nongastrointestinal tumors, severity of cancer stage, percentage of weight loss, number of symptoms per patient, Eastern Cooperative Oncology Group (ECOG) performance status, and nutritional risk score. CONCLUSIONS: The statistical analysis has validated the classification by identifying stages with different severity of cachexia. This classification could be adopted within a comprehensive oncologic approach to the weight-losing patients, until more specific diagnostic techniques are available in clinical practice.
Authors: Richard F Dunne; Karen M Mustian; Jose M Garcia; William Dale; Reid Hayward; Breton Roussel; Mary M Buschmann; Bette J Caan; Calvin L Cole; Fergal J Fleming; Joe V Chakkalakal; David C Linehan; Aram F Hezel; Supriya G Mohile Journal: Curr Opin Support Palliat Care Date: 2017-12 Impact factor: 2.302
Authors: N Johns; B H Tan; M MacMillan; T S Solheim; J A Ross; V E Baracos; S Damaraju; K C H Fearon Journal: J Genet Date: 2014-12 Impact factor: 1.166
Authors: David Blum; Aurelius Omlin; Ken Fearon; Vickie Baracos; Lukas Radbruch; Stein Kaasa; Florian Strasser Journal: Support Care Cancer Date: 2010-03 Impact factor: 3.603
Authors: Federico Bozzetti; Luigi Mariani; Salvatore Lo Vullo; Maria Luisa Amerio; Roberto Biffi; Giovanni Caccialanza; Giorgio Capuano; Giovanni Capuano; Isabel Correja; Luca Cozzaglio; Angelo Di Leo; Leonardo Di Cosmo; Concetta Finocchiaro; Cecilia Gavazzi; Antonello Giannoni; Patrizia Magnanini; Giovanni Mantovani; Manuela Pellegrini; Lidia Rovera; Giancarlo Sandri; Marco Tinivella; Enrico Vigevani Journal: Support Care Cancer Date: 2012-08 Impact factor: 3.603